Use of Long-Acting Injectable Antipsychotics in Inpatients with Schizophrenia Spectrum Disorder in an Academic Psychiatric Hospital in Switzerland

Stephan Reymann; Georgios Schoretsanitis; Stephan T Egger; Alexey Mohonko; Matthias Kirschner; Stefan Vetter; Philipp Homan; Erich Seifritz; Achim Burrer

doi:10.3390/jpm12030441

Use of Long-Acting Injectable Antipsychotics in Inpatients with Schizophrenia Spectrum Disorder in an Academic Psychiatric Hospital in Switzerland

J Pers Med. 2022 Mar 11;12(3):441. doi: 10.3390/jpm12030441.

Authors

Stephan Reymann¹, Georgios Schoretsanitis¹, Stephan T Egger¹, Alexey Mohonko¹, Matthias Kirschner¹, Stefan Vetter¹, Philipp Homan^{1

2}, Erich Seifritz¹, Achim Burrer¹

Affiliations

¹ Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zurich, 8032 Zurich, Switzerland.
² Neuroscience Center Zurich, University of Zurich, 8057 Zurich, Switzerland.

Abstract

Long-acting injectable antipsychotics (LAIs) offer many benefits to patients with schizophrenia spectrum disorder (SSD). They are used with very different frequencies due to questions of eligibility or patients and prescribers' attitudes towards LAI use. We assessed the prescribing rates of LAIs in a large academic psychiatric hospital with a public service mandate in Switzerland and compared them with other countries and health care systems. To our knowledge, this study is the first to investigate inpatient LAI use in Europe. Medical records of all patients diagnosed with SSD discharged from the Clinic of Adult Psychiatry of the University Hospital of Psychiatry Zurich over a 12 month period from January to December 2019 were evaluated regarding the prescribed antipsychotics at the time of discharge. The rates of use of LAIs among all patients and among patients receiving LAI-eligible antipsychotic substances were assessed retrospectively. We assessed records of 885 patients with SSD. Among all cases, 13.9% received an LAI. Among patients who received antipsychotic medication that was eligible for LAI use (n = 434), 28.1% received an agent as an LAI. LAI use included paliperidone palmitate (69.9%), aripiprazole monohydrate (14.6%), risperidone (4.9%) and first-generation LAIs (9.8%). Compared to international frequencies of LAI administration, the prescription rate of LAIs in SSD patients was low. Further studies will evaluate patient- and prescriber-related reasons for this low rate.

Keywords: antipsychotic; depot; inpatient; long-acting injectable; prescribing pattern; schizoaffective; schizophrenia; schizophrenia spectrum disorder.